| Afimoxifene | |
|---|---|
|
(Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol |
|
|
Other names
4-hydroxytamoxifen |
|
| Identifiers | |
| CAS number | 68392-35-8 |
| PubChem | 449459 |
| ChemSpider | 395987 |
| KEGG | D06551 |
| ChEMBL | CHEMBL489 |
| Jmol-3D images | Image 1 Image 2 |
|
|
|
|
| Properties | |
| Molecular formula | C26H29NO2 |
| Molar mass | 387.51396 |
| (verify) (what is: /?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Afimoxifene[1] (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen.[2] Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.[1]
Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.[3]
A study in France on 55 women showed that rubbing afimoxifene on the skin was as good as tamoxifen tablets at slowing breast cancer growth. A US trial will compare 6 weeks use before breast cancer surgery. Skin application can reduce systemic levels by a factor of nine and this is expected to reduce the unpleasant side-effects of tamoxifen.[4]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||